The global breast lesion localization methods market is experiencing positive growth due to various factors. The market offers several benefits such as increased accuracy and precision in localizing breast lesions, aiding in more targeted and effective surgical interventions. Advanced technologies and techniques, such as wire-guided localization, radioactive seed localization, and magnetic tracers, are improving localization procedures. These methods provide improved patient comfort, reduced procedure time, and better surgical outcomes.
Access Full Report: https://www.databridgemarketresearch.com/reports/global-breast-lesion-localization-methods-market
Data Bridge Market Research analyses that the Breast Lesion Localization Methods Market is expected to grow at a CAGR of 13.0% in the forecast period of 2022 to 2029 and is expected to reach USD 648.66 million by 2029 from USD 244 million in 2021. Governments and healthcare organizations worldwide are actively involved in breast cancer awareness programs, screening campaigns, and research initiatives. Increased funding and support for breast cancer diagnosis and treatment are driving the development and adoption of advanced breast lesion localization methods.
Key Findings of the Study
Shift toward minimally invasive procedures is expected to drive the market's growth rate
The shift towards minimally invasive procedures in breast surgeries is driven by the desire to minimize patient discomfort, reduce scarring, and promote faster recovery. Breast lesion localization methods play a vital role in these procedures by precisely marking the target area for surgical intervention. Accurately localizing the lesion, surgeons can remove or sample the affected tissue while minimizing the impact on healthy surrounding tissue, leading to improved cosmetic outcomes and better preservation of breast function.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Wire Localization, Radioisotope Localization, Radioactive Seed Localization, Radio Occult Lesion Localization, Magnetic Tracers and Others), Biopsy Techniques (Fine Needle Aspiration Biopsy, Core Needle Biopsy, Surgical Biopsy, Incisional Biopsy, Excisional Biopsy, Vacuum-Assisted Breast Biopsy and Others), End User (Diagnostic Centres, Hospitals, Oncology Clinics and Ambulatory Surgical Centres) Usage (Tumor Identification and Sentinel Lymph Node Lumpectomy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
SOMATEX Medical Technologies GmbH (Germany), BD (Becton, Dickinson and Company) (U.S.), Merit Medical Systems (U.S.), Endomagnetics Ltd (U.K.), Cook Medical (U.S.), Intramedical Imaging, LLC (U.S.), Ranfac Corp. (U.S.), Medtronic (Ireland), Stryker (U.S.), Wright Medical Group N.V. (Netherlands), Zimmer Biomet (U.S.), Smith+Nephew (U.K.), Boston Scientific Corporation (U.S.), Organogenesis Inc. (U.S.), Arthrex, Inc. (U.S.), Orthofix Medical Inc. (U.S.), Kubtec X-Ray (U.S.), Miltenyi Biotec GmbH (Germany), Naviscan (U.S.), PerkinElmer Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The breast lesion localization methods market is segmented on the basis of type, biopsy techniques, end user, and usage
- On the basis of type, the breast lesion localization methods market is segmented into wire localization, radioisotope localization, radioactive seed localization, radio occult lesion localization, magnetic tracers, and others. Wire localization dominates the breast lesion localization methods market due to its long-standing use, established techniques, and wide acceptance among surgeons for precise localization of breast lesions prior to surgical procedures with a CAGR of 12% in the forecast period of 2022 to 2029.
In 2022, the wire localization dominates the type segment of the breast lesion localization methods market
In 2022, wire localization dominates the type segment of the breast lesion localization methods market with a CAGR of 12% owing to its widespread acceptance among surgeons, its long history of use, and its proven methods for precisely localizing breast lesions before surgery in the forecast period of 2022-2029.
- On the basis of biopsy techniques, the breast lesion localization methods market is segmented into fine needle aspiration biopsy, core needle biopsy, surgical biopsy, incisional biopsy, excisional biopsy, vacuum-assisted breast biopsy, and others. Fine Needle Aspiration Biopsy (FNAB) is dominating the biopsy technique segment of the market due to its simplicity, cost-effectiveness, and accuracy. It involves extracting cells or fluid from a lesion using a thin needle for cytological examination, aiding in the diagnosis of breast lesions with a 12.5% CAGR in the forecast period of 2022-2029.
- On the basis of end user, the breast lesion localization methods market is segmented into diagnostic centres, hospitals, oncology clinics and ambulatory surgical centres. Hospitals segment dominates the end user segment of the breast lesion localization methods market due to the availability of comprehensive healthcare facilities, advanced imaging technologies, and the ability to perform a wide range of surgical interventions in a hospital setting with a CAGR of 12.8% in the forecast period of 2022 to 2029.
In 2022, the hospitals segment dominates the end user segment of the breast lesion localization methods market
In 2022, the hospitals segment dominates the end user segment of the breast lesion localization methods market owing to the accessibility of advanced imaging technologies, comprehensive healthcare facilities, and the capacity to carry out a variety of surgical procedures in a hospital setting with a CAGR of 12.8% in the forecast period of 2022 to 2029.
- On the basis of usage, the breast lesion localization methods market is segmented into tumor identification and sentinel lymph node lumpectomy. Tumor Identification segment dominates the usage of breast lesion localization methods as it plays a crucial role in accurately identifying and localizing tumors, guiding surgeons in precise surgical interventions and ensuring optimal tumor removal and treatment outcomes.
Major Players
Data Bridge Market Research recognizes the following companies as the major breast lesion localization methods market players in breast lesion localization methods market are Cook Medical (U.S.), Intramedical Imaging, LLC (U.S.), Ranfac Corp. (U.S.), Medtronic (Ireland), Stryker (U.S.), Wright Medical Group N.V. (Netherlands)
Market Development
- In 2022, Molli was introduced in hospitals across Canada by MOLLI Surgical and Sunnybrook Health Sciences Centre. This launch aids in more accurate tumor localization for precise surgery.
- In 2022, The Scout Bx delivery system from Merit Medical System, a wire-free breast localization tool used during stereotactic and MRI-guided biopsy in breast cancer surgery, has received FDA approval.
- In 2021, The acquisition of Somatex Medical Technologies by Hologic Inc. has been completed, allowing Hologic Inc. to expand their line of breast markers.
- In 2020, A product called Magseed was introduced by Endomagnetics Ltd. It is implanted in the affected breast before surgery and uses a probe to show the surgeon precisely where the cancerous tissue is located.
- In 2019, Cook's line of breast localization and soft tissue biopsy needles was acquired by IZI. As a result, IZI will be able to penetrate newer markets.
Regional Analysis
Geographically, the countries covered in the breast lesion localization methods market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
Asia Pacific is the dominant region in the breast lesion localization methods market during the forecast period 2022-2029
The dominance of Asia Pacific in the global breast lesion localization methods market is driven by multiple factors. The region boasts well-established players and ongoing efforts to improve healthcare infrastructure. Governments in APAC countries are increasing spending on breast cancer research, while public awareness of early detection importance is growing. Additionally, major players are focusing on emerging Asian countries, further supporting market growth. These factors collectively contribute to Asia Pacific's leading position in the breast lesion localization methods market.
For more detailed information about the breast lesion localization methods market report, click here – https://www.databridgemarketresearch.com/reports/global-breast-lesion-localization-methods-market
